Cortexolone 17α-propionate (developmental code name CB-03-01), or 11-deoxycortisol 17α-propionate, is a synthetic steroidal antiandrogen–specifically, an androgen receptor antagonist – which is used as a topical medication in the treatment of androgen-dependent conditions including acne vulgaris and androgenic alopecia (male-pattern hair loss). It is the C17α propionate ester of 11-deoxycortisol (cortexolone); C17α esters of 11-deoxycortisol were unexpectedly found to possess antiandrogen activity, and cortexolone 17α-propionate was selected for development based on its optimum drug profile.

Function:
CB-03-01 is the drug for the treatment of hair loss dwindled. It has same function and application with RU58841 and Setipiprant.
CB-03-01 is a molecule that acts at the level of the skin, blocking dihydrotestosterone (DHT) from binding to the receptor in the cell. The molecule has a unique mechanism that acts at the skin surface, and is quickly metabolized to free inactive cortexolone, a substance naturally found in the body. The molecule has been evaluated in a variety of animal models as well as initial human trials in Europe. The results of these studies demonstrate that CB-03-01 appears to have potent activity without significant local or systemic side effects.